Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Basic and clinical studies on ApoE gene typing by line probe assay (LiPA) as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan.
Nishimura T, Takeda M, Shinosaki K, Nishikawa T, Nakamura Y, Yoshida Y, Sasaki H, Arai H, Hirai S, Shouji M, Isse K, Tanaka K, Hamamoto M, Yamamoto H, Matsubayashi T, Nakashima K, Urakami K, Adachi Y, Nakamura S, Toji H, Yoshida H. Nishimura T, et al. Among authors: toji h. Methods Find Exp Clin Pharmacol. 1998 Nov;20(9):793-9. Methods Find Exp Clin Pharmacol. 1998. PMID: 10022033
Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan.
Nishimura T, Takeda M, Nakamura Y, Yosbida Y, Arai H, Sasaki H, Shouji M, Hirai S, Khise K, Tanaka K, Hamamoto M, Yamamoto H, Matsubayashi T, Urakami K, Adachi Y, Nakashima K, Toji H, Nakamura S, Yoshida H. Nishimura T, et al. Among authors: toji h. Methods Find Exp Clin Pharmacol. 1998 Apr;20(3):227-35. Methods Find Exp Clin Pharmacol. 1998. PMID: 9646285
Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group.
Shoji M, Matsubara E, Murakami T, Manabe Y, Abe K, Kanai M, Ikeda M, Tomidokoro Y, Shizuka M, Watanabe M, Amari M, Ishiguro K, Kawarabayashi T, Harigaya Y, Okamoto K, Nishimura T, Nakamura Y, Takeda M, Urakami K, Adachi Y, Nakashima K, Arai H, Sasaki H, Kanemaru K, Yamanouchi H, Yoshida Y, Ichise K, Tanaka K, Hamamoto M, Yamamoto H, Matsubayashi T, Yoshida H, Toji H, Nakamura S, Hirai S. Shoji M, et al. Among authors: toji h. Neurobiol Aging. 2002 May-Jun;23(3):363-70. doi: 10.1016/s0197-4580(01)00309-8. Neurobiol Aging. 2002. PMID: 11959397
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Sims JR, et al. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. JAMA. 2023. PMID: 37459141 Free PMC article.
23 results